Gastroenterology
Browse by
Research outputs from the Gastroenterology department at the RD&E.
Recent Submissions
-
HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn's Disease
(Elsevier, 2020-01)Anti-tumor necrosis factor (anti-TNF) therapies are the most widely used biologic drugs for treating immune-mediated diseases, but repeated administration can induce the formation of anti-drug antibodies. The ability to ... -
Palliative care in liver disease: what does good look like?
(BMJ, 2019-09)The mortality rate from chronic liver disease in the UK is rising rapidly, and patients with advanced disease have a symptom burden comparable to or higher than that experienced in other life-limiting illnesses. While ... -
Practice pattern variability in the management of acute severe colitis: a UK provider survey
(BMJ, 2019-08)Lack of comparative trial data on dosing regimens of infliximab in patients with acute severe ulcerative colitis (ASUC) failing intravenous corticosteroids has resulted in variability of rescue regimes in ASUC with potential ... -
British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults
(BMJ, 2019-12)Ulcerative colitis and Crohn's disease are the principal forms of inflammatory bowel disease. Both represent chronic inflammation of the gastrointestinal tract, which displays heterogeneity in inflammatory and symptomatic ... -
Factors associated with depression in people with inflammatory bowel disease: The relationship between active disease and biases in neurocognitive processing
(Wiley, 2019-08)Depression is common among people with inflammatory bowel disease (IBD), though the causes remain unclear. We conducted a cross-sectional study to investigate the role of emotional processing biases in contributing to ... -
Drug toxicity: personalising IBD therapeutics - the use of genetic biomarkers to reduce drug toxicity
(Springer, 2019-05)Adverse drug reactions (ADRs) result in morbidity and mortality as well as placing a significant financial burden on health-care resources. In Europe and North America, they are responsible for approximately 6% of all ... -
A blood-based prognostic biomarker in IBD
(BMJ, 2019-08)We have previously described a prognostic transcriptional signature in CD8 T cells that separates patients with IBD into two phenotypically distinct subgroups, termed IBD1 and IBD2. Here we sought to develop a blood-based ... -
Complicated disease and response to initial therapy predicts early surgery in paediatric Crohn's disease: results from the Porto Group GROWTH study
(Oxford Academic, 2019-06-03)The ability to predict risk for poor outcomes in Crohn's disease (CD) would enable early treatment intensification. We aimed to identify children with CD with complications at baseline and throughout the study period who ... -
Genome-wide association study of microscopic colitis in the UK Biobank confirms immune-related pathogenesis
(Oxford Academic, 2019-05-24)The causes of microscopic colitis are currently poorly understood. Previous reports have found clinical associations with coeliac disease and genetic associations at the HLA locus on the ancestral 8.1 haplotype. We ... -
Diagnostic accuracy and usability of home calprotectin testing
(European Crohn's and Colitis Organisation, 2019-01)Faecal calprotectin (FC) is a reliable and non-invasive stool biomarker that is useful in monitoring inflammation in patients with IBD. Testing is routinely performed in a laboratory by enzyme-linked immunosorbent assay ... -
Dosing, durability of haemoglobin response and safety of iron isomaltoside in outpatients with gastrointestinal diseases
(2019-06)Poster presented at the British Society of Gastroenterology 2019 Annual Conference, 17th-20 June 2019. -
Fever and tachypnoea in a child
(BMJ, 2019-05-10) -
Association between level of fecal calprotectin and progression of Crohn's Disease
(Elsevier, 2019-02-14)Mucosal healing is associated with improved outcomes in patients with Crohn’s disease (CD), but assessment typically requires ileocolonoscopy. Calprotectin can be measured in fecal samples to determine luminal disease ... -
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
(Elsevier, 2019-05)Anti-TNF drugs are effective treatments for the management of Crohn's disease but treatment failure is common. We aimed to identify clinical and pharmacokinetic factors that predict primary non-response at week 14 after ... -
Association of genetic variants in NUDT15 with thiopurine-induced myelosuppression in patients with inflammatory bowel disease
(JAMA, 2019-02)Use of thiopurines may be limited by myelosuppression. TPMT pharmacogenetic testing identifies only 25% of at-risk patients of European ancestry. Among patients of East Asian ancestry, NUDT15 variants are associated with ... -
Inflammatory bowel disease in children and adolescents.
(Canadian Medical Association, 2019-02-11) -
Systematic review of definitions and outcome measures for return of bowel function after gastrointestinal surgery.
(Wiley, 2018-10)Ileus is common after gastrointestinal surgery and has been identified as a research priority. Several issues have limited previous research, including a widely accepted definition and agreed outcome measure. This review ... -
Wide variation in the use and understanding of therapeutic drug monitoring for anti-TNF agents in inflammatory bowel disease: an inexact science?
(Taylor & Francis, 2018-10-24)We aimed to understand the way in which therapeutic drug monitoring (TDM) is used, understood and interpreted for anti-TNF agents in IBD.
RSS 1.0